Miriam E. Mossoba
Impact in
-
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Cancer Cells and Metastasis
Papers in
- Oncology 10
- CAR-T cell therapy research 6
-
- Drug-Induced Hepatotoxicity and Protection 7
- Pharmacogenetics and Drug Metabolism 4
- Co-authors
- Jeffrey A. Medin (7 shared papers)Robert L. Sprando (15 shared papers)Giulio Francia (3 shared papers)Shan Man (3 shared papers)Robert S. Kerbel (3 shared papers)Urban Emmenegger (3 shared papers)Alicia Viloria‐Petit (1 shared paper)Daniel J. Hicklin (1 shared paper)
- Journals
- Clinical Cancer Research (4 papers)Toxicology Reports (3 papers)Molecular Cancer Therapeutics (2 papers)Molecular Therapy (2 papers)Toxicology in Vitro (2 papers)
- Partner nations
- United StatesCanadaBulgaria
In The Last Decade
Miriam E. Mossoba
28 papers receiving 420 citations
Peers
Comparison fields: 5 of 82
- Oncology 167
- Biotechnology 43
- Immunology 92
- Cancer Research 59
- Radiology, Nuclear Medicine and Imaging 64
Countries citing papers authored by Miriam E. Mossoba
This map shows the geographic impact of Miriam E. Mossoba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miriam E. Mossoba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miriam E. Mossoba more than expected).
Fields of papers citing papers by Miriam E. Mossoba
This network shows the impact of papers produced by Miriam E. Mossoba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miriam E. Mossoba. The network helps show where Miriam E. Mossoba may publish in the future.
Co-authors
The 25 scholars most cited alongside Miriam E. Mossoba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 116 | |
| 2 | 2011 | 36 | |
| 3 | 2009 | 33 | |
| 4 | 2019 | 24 | |
| 5 | 2020 | 23 | |
| 6 | 2008 | 22 | |
| 7 | 2008 | 21 | |
| 8 | 2006 | 16 | |
| 9 | 2009 | 16 | |
| 10 | 2010 | 14 | |
| 11 | 2011 | 12 | |
| 12 | 2017 | 12 | |
| 13 | 2020 | 11 | |
| 14 | 2006 | 10 | |
| 15 | 2016 | 7 | |
| 16 | 2015 | 7 | |
| 17 | 2017 | 6 | |
| 18 | 2019 | 6 | |
| 19 | 2016 | 6 | |
| 20 | 2020 | 6 |
About Miriam E. Mossoba
Miriam E. Mossoba is a scholar working on Oncology, Pharmacology, Immunology, Molecular Biology and Organic Chemistry, having authored 29 papers that have together received 425 indexed citations. Recurring topics across this work include Drug-Induced Hepatotoxicity and Protection (7 papers), CAR-T cell therapy research (6 papers), Immunotherapy and Immune Responses (6 papers), Edible Oils Quality and Analysis (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), T-cell and B-cell Immunology (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Carcinogens and Genotoxicity Assessment (3 papers). The work is most often cited by research in Oncology (167 citations), Biotechnology (43 citations), Immunology (92 citations), Cancer Research (59 citations) and Radiology, Nuclear Medicine and Imaging (64 citations). Miriam E. Mossoba has collaborated with scholars based in United States, Canada and Bulgaria. Frequent co-authors include Jeffrey A. Medin, Robert L. Sprando, Giulio Francia, Shan Man, Robert S. Kerbel, Urban Emmenegger, Alicia Viloria‐Petit, Daniel J. Hicklin, Thomas J. Flynn and Daniel H. Fowler. Their work appears in journals such as Clinical Cancer Research, Toxicology Reports, Molecular Cancer Therapeutics, Molecular Therapy and Toxicology in Vitro.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.